Moleculin Biotech is trading 5.3% down at $8.28, with no company-specific announcement or clear catalyst identified for the October 29, 2026 decline. - Its latest listed update was an October 20 CEO Corner segment about the MIRACLE trial, not a new announcement explaining the move. - Broader markets are weaker, but available evidence does not establish that market conditions caused the stock’s decline.